Back to search

Article

A phase Ib trial evaluating the safety, efficacy, and immunologic effects of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer

2022-09-13

Abstract excerpt

<title>Abstract</title> <p>Background Chemoimmunotherapy with anti-programmed cell death 1/ligand 1 and cytotoxic chemotherapy is a promising therapeutic modality for women with triple-negative breast cancer, but questions remain regarding optimal chemotherapy backbone and biomarkers for patient selection. Methods We report final outcomes from a phase Ib trial evaluating pembrolizumab (200mg IV every 3 weeks)...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e86985b3-acb3-5283-9170-c32c88a24ff6
DOI
10.21203/rs.3.rs-1954085/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A phase Ib trial evaluating the safety, efficacy, and immunologic effects of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancerDOI 10.21203/rs.3.rs-1954085/v1
Mass cytometry uncovers distinct blood myeloid phenotypes linked to clinical responses during gastric cancer chemoimmunotherapy.Semantic proximity
BRCA1/2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisSemantic proximity
Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.Semantic proximity
Targeted spatial profiling identifies a CD8A − LARS axis associated with neoadjuvant chemotherapy resistance in triple-negative breast cancerSemantic proximity
Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast CancersSemantic proximity
Prediction of pan-solid tumor pembrolizumab benefit by integrating tumor mutation and gene expression profilingSemantic proximity
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsSemantic proximity
The Correlation of PD-L1 Expression in Metaplastic BreastCancers with Clinical-Pathological Features and PrognosisSemantic proximity
Immunogenomic Profiling and Pathological Response Results From a Clinical Trial of Docetaxel and Carboplatin in Triple Negative Breast CancerSemantic proximity
CD38 <sup>hi</sup> CD19 <sup>dim</sup> cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockadeSemantic proximity
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.Semantic proximity
Microtubule targeting agents influence the clinical benefit of immune response in early breast cancerSemantic proximity
Select a neighboring publication to make it the new centre.